The CFRC is comprised of 50 faculty members from ten departments, who provide research strengths in areas ranging from basic science to clinical investigations. Its members garner more than $13 M/yr in extramural grants and contracts to support our CF research efforts.
CFRC Funding Opportunities:
2023 CFRC Impact Grants
We are pleased to announce a new round of Pilot and Feasibility Grants to be funded by the University of Pittsburgh Cystic Fibrosis (CF) Research Center (CFRC) starting in July 2023. These grants are designed to attract new investigators, or established investigators with new ideas, to the CF research area. They provide seed funds for the acquisition of data that will enable expanded applications to the NIH or the Cystic Fibrosis Foundation (CFF). These proposals should be innovative, but also targeted to the mission of the CFF.
Grants are funded for up to two years, and they have an upper funding limit of $50,000/yr.
Research areas for this program should align with the research priorities described in the most recent strategic plan from the Cystic Fibrosis Foundation, which can be found here: https://www.cff.org/about-us/our-strategic-plan.
Applications must include:
- Budget (form attached) for 1 or 2 years
- NIH Biosketches for principal and co-investigators
- Specific Aims, Significance, including a paragraph describing relevance of the project to the mission of CFF, and Approach, not to exceed 3 pages
Dates and Deadlines:
Application Deadline: May 12, 2023
Notification of Award: June 2, 2023
Funding starts: July 1, 2023
Investigators at the University of Pittsburgh and Carnegie Mellon University are eligible.
Both basic and translational research applications are welcome.
Questions? Please contact Tim Corcoran (tec23@pitt.edu).
Applications should be submitted to Katie Nauman (naumanke@upmc.edu) by 5/12/23.
Current and Past Pilot/Feasibility Projects:
Pilot Start Date |
PI |
Department |
Title of Pilot |
---|---|---|---|
June 1 2018 |
Vaughn Cooper |
MMG |
Response of the lung microbiome to commonly used inhaled antibiotics |
October 1 2017 |
Carlos Camacho |
Computational and
|
Discovering novel inhibitors of the E3 ubiquitin ligase CHIP using a rational gemonic/structure-based screen |
June 1 2017 |
Alison Morris/Barbara Methé |
Pulmonary |
Microbiome-host interactions during cystic fibrosis pulmonary exaebations using multi-omics approaches |
June 1 2016 |
Timothy Hand |
Pediatrics |
Role of immune response to the intestinal microbiota in Cystic Fibrosis |
June 1 2015 |
John Alcorn |
Pediatrics |
The impact of CFTR dysfunction on epithelial host defense against S. aureus |
June 1 2014 |
Agnes Urban |
Pediatrics |
LMTK2 and TGF Beta Signaling in Human Airway Epithelial Cells |
June 1 2013 |
Marcel Bruchez |
CMU-Biological Sciences |
Discovery of New Gene Targets for CF Therapies |
June 1 2012 |
Ronald Montelaro |
MMG |
Engineered Cationic antimicrobial peptides (eCAP) for the treatment of viral and bacterial respiratory infections in CF patients |
June 1 2012 |
Xinyu Lio |
Chemistry |
Decode the Viculence Signaling Network of Pathogenic Bacteria in Cystic Fibrosis Lung Infection |
June 1 2011 |
Thomas Gilbert |
Surgery |
Ex Vivo Model of Cystic Firbrosis |
June 1 2011 |
Jennifer Bomberger |
MMG |
Pseudomonas-vial Co-infection in Cystic Fibrosis |